Today, our panel of experts will explore the treatment landscape and impact of multiple sclerosis [MS], unmet ... think it’s important to focus on the epidemiology, some of the clinical ...

The epidemiology of multiple sclerosis (MS) is well studied owing to its prevalence and position as the main cause of non-traumatic disability among young adults. The usual age of onset for ...

“It started with the observation that the epidemiology of multiple sclerosis is quite unique because there is a very striking geographical distribution,” Professor Ascherio told IFLScience ...

Multiple Sclerosis Epidemiology and Patient Population (In the US, EU5, and Japan) 8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices. 9.

SUFFICIENT information exists concerning the prevalence and the incidence patterns of multiple sclerosis in North America 1,2 so that communities can now be recognized and statistical ...

Multiple sclerosis (MS) is a complex and serious autoimmune disease for which there is no cure, and its prevalence is rising globally – especially in countries with advanced economies. Scientists need ...

Multiple sclerosis (MS) is one of the most widespread disabling neurological conditions of young adults around the world. It affects almost 1 million people in the United States, and about 2.9 ...

"We found a much higher prevalence of multiple sclerosis in Black Americans than previously thought," the investigators said. Other recent research has also focused on better understanding MS in ...

“It started with the observation that the epidemiology of multiple sclerosis is quite unique because there is a very striking geographical distribution,” Professor Ascherio told IFLScience.

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Bristol-Myers Squibb, TG Therapeutics, Hoffmann-La Roche, Atara Biotherapeutics ...